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Abstract. The aim of the present work was to produce 3D-printed oral dosage forms with
a sufficient drug dose displaying various release profiles. Hot-melt extrusion was utilized to
produce drug-loaded feedstock material that was subsequently 3D-printed into 6, 8, and 10 ×
2.5 mm tablets with 15% and 90% infill levels. The prepared formulations contained 30% (w/
w) isoniazid in combination with one or multiple pharmaceutical polymers possessing suitable
properties for oral drug delivery. Thirteen formulations were successfully hot-melt extruded
of which eight had properties suitable for fused deposition modeling 3D printing.
Formulations containing HPC were found to be superior regarding printability in this study.
Filaments with a breaking distance below 1.5 mm were observed to be too brittle to be fed
into the printer. In addition, filaments with high moisture uptake at high relative humidity
generally failed to be printable. Different release profiles for the 3D-printed tablets were
obtained as a result of using different polymers in the printed formulations. For 8 mm tablets
printed with 90% infill, 80% isoniazid release was observed between 40 and 852 min. Drug
release characteristics could further be altered by changing the infill or the size of the printed
tablets allowing personalization of the tablets. This study presents novel formulations
containing isoniazid for prevention of latent tuberculosis and investigates 3D printing
technology for personalized production of oral solid dosage forms enabling adjustable dose
and drug release properties.
KEY WORDS: 3D printing; personalized medicine; hot-melt extrusion; immediate release; sustained
release.
INTRODUCTION
Tuberculosis, an infectious disease caused by Mycobacte-
rium tuberculosis typically affecting the lungs, is the ninth most
common cause of death worldwide (1).According to estimations
by the World Health Organization (WHO), 10.4 million people
fell ill with tuberculosis in 2016 and almost two million deaths
were estimated among the people infected with the disease.
Most deaths caused by tuberculosis could successfully be
prevented with early diagnosis, suitable treatment, and preven-
tion of latent tuberculosis in identified risk groups. Therefore,
preventive treatment for tuberculosis and latent tuberculosis is
needed (1). Treatment of latent tuberculosis with isoniazid
monotherapy daily for 6months is recommended for both adults
and children in countries with both high and low disease
prevalence. Currently, the recommended isoniazid dose for
latent tuberculosis is 5 mg/kg for adults and 7–15 mg/kg for
children with a maximum dose of 300 mg/day (2).
Age has been reported to have an effect on the
pharmacokinetics of isoniazid since the drug is metabolized
more rapidly in children (3) due to, e.g., increased first pass
effect as children have a larger liver in comparison to their
body weight as compared to adults (4). Other factors that
have been identified to affect the isoniazid dose required are
the maturation of the N-acetyl transferase 2 (NAT2) enzyme,
the acetylation rate (fast, intermediate, and slow) of isoniazid
due to different genotypes of NAT2, and body surface area to
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name a few (3–5). Isoniazid is listed on the Best Pharmaceu-
ticals for Children Act, which is a priority list of needs in
pediatric therapeutics for 2017 given out by the National
Institutes of Health, where there has been identified a
scientific need to advance the technology and design of the
dosage forms to improve adherence and effectiveness of the
isoniazid therapy (6). Individualized doses are needed in the
treatment of tuberculosis as it has been reported that fast
acetylators of isoniazid typically show subtherapeutic plasma
exposure values where on the other hand, slow or interme-
diate acetylators may require a lower dose to achieve the
recommended plasma values of 3–6 mg/L (7). Individualized
drug therapies may help to solve the recognized unmet need
for isoniazid as personalized therapies not only increase the
compliance but also the effectiveness and success of a therapy
(8,9). It has moreover been reported that over 80% of the
adverse effects may originate from inappropriate dosing or
dose combinations (10). These factors highlight that person-
alized treatment of isoniazid may lead to better treatment
outcomes, especially in children who most likely will undergo
physiological changes during the time span of the lengthy
treatment. Not only the dose but also the tablet geometry can
be adjusted during the treatment regimen to tailor the drug
release if so required for the treated patient.
Three-dimensional (3D) printing, a rapid prototyping
technology based on principles of additive manufacturing that
allows the manufacturing of dosage forms with different
geometrical shapes, has recently been explored in the
biomedical and pharmaceutical field (8,11–15). 3D printing
is attractive to scientists and manufacturers in the pharma-
ceutical field that currently are bound to conventional
manufacturing methods that produce fixed-dose tablets with
limited possibilities of personalization (16–20). Manufacturing
of small batches or even a single dose utilizing 3D printing is
considered cost-effective (13,21,22) compared to traditional
pharmaceutical manufacturing methods that on the contrary
are cost-effective when large batches of the same dosage form
(same size and dose level) are produced. Production of small
batches plays a vital role in personalized drug therapies,
which need to be produced on-demand and close to the
patient to be able to prepare patient-tailored treatments
needed at that specific time (16,17).
Initially, 3D printing in the pharmaceutical field mainly
involved printing of drug-loaded commercially available
filaments that were developed for the fused deposition
modeling (FDM) 3D printers (e.g., polylactic acid, acryloni-
trile butadiene styrene, and polycaprolactone) (18,23,24).
These types of polymers typically displayed a sustained drug
release that is more suitable for implants than oral dosage
forms. The oral route for administration of drugs still today
remains the favored choice by patients (19,25). A logical
trend is, therefore, to move towards studying polymers that
would be suitable for 3D printing of oral dosage forms as well
as utilizing methods that allow for sufficient drug loading
compared to the soaking methods previously used to
incorporate the drug in the commercially available filaments.
Lately, various polymer–drug combinations have been hot-
melt extruded (HME) and their suitability for FDM printing
of oral tablets has been explored (26–32). Readers interested
in additional applications of pharmaceutical 3D printing are
referred to the following extensive reviews (21,22,33,34).
The aim of the current study was to produce FDM 3D
printable filaments consisting of FDA-approved pharmaceu-
tical grade polymers by utilizing hot-melt extrusion. The goal
was to formulate and produce filaments with sufficient drug
loading and variable release characteristics (immediate and
controlled release) that subsequently could be used in a 3D
printer to produce differently sized solid oral dosage forms
with a relevant dose of isoniazid. Furthermore, the effect on
the release properties originating from the printing process
itself at elevated temperatures as well as different properties
of the printed tablets, namely infill and tablet size, was
studied. In addition, the printability with regard to the
mechanical properties of the produced filaments was investi-
gated. To the best of our knowledge, there are no previous
studies on 3D-printed oral isoniazid dosage forms that could
have potential in manufacturing at hospital pharmacies, wards
at the point-of-care, or which could contribute to on-demand
dose dispensing in developing countries.
MATERIALS
Isoniazid > 98% was purchased from TCI America
(Portland, OR, USA). Hydroxypropylmethylcellulose
(HPMC, Benecel™ grade E5 Pharm and K100M Pharm)
and hydroxypropylcellulose (HPC, Klucel™ grade
EF Pharm, MW 80,000 and HF Pharm, MW 1,150,000) were
donated by Ashland (Covington, KY, USA). Polyethylene
oxide (PEO, Sentry™ Polyox™ WSR N-80 NF, MW approx.
200,000, and Sentry™ Polyox™ WSR N-750 NF, MWapprox.
300,000) was supplied by Dow Chemical Company (Midland,
MI, USA). Eudragit® RS PO, RL PO and L 100 were kindly
provided by Evonik Industries AG (Essen, Germany).
Triethyl citrate ≥ 99% (TEC) was purchased from Sigma-
Aldrich (Darmstadt, Germany), and Kolliphor® TPGS
(vitamin E polyethylene glycol succinate, d-alpha tocopherol
content min 250 mg/g) was acquired from BASF
(Ludwigshafen, Germany). Buffering agents, potassium
dihydrogen phosphate and sodium hydroxide pellets were of
analytical grade and purchased from Merck (Darmstadt,
Germany) and Sigma-Aldrich (Darmstadt Germany), respec-
tively. Polylactic acid (PLA) 3D printable filament (PLA
natural) with a diameter of 1.75 mm obtained from MakerBot
(MakerBot Industries, NY, USA) was used as received.
METHODS
Hot-Melt Extrusion
A total of 13 formulations containing 30% (w/w)
isoniazid and varying polymers and plasticizers were pre-
pared in 50 g batches (Table I). The powder blends were
mixed in a closed plastic container on a Maxiblend
(GlobePharma, New Brunswick, NJ, USA) at 25 rpm for a
minimum of 20 min before being extruded as cylindrical
filaments utilizing a Thermo Fisher Process 11 mm co-rotating
twin-screw extruder (Waltham, MA, USA). A standard screw
assembly with three mixing zones was used. Barrel temper-
atures between 100 and 155°C and a screw speed of 50 rpm
were used to extrude the different formulations. Polymer
melts were extruded through a circular die (⌀ 2 mm) and
guided onto a conveyor belt for cooling and fine-tuning of the
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filament diameter. The diameter of the extruded filament was
adjusted by changing the speed of the conveyor belt. The hot-
melt extruded filaments were coiled, stored in sealed zip lock
bags protected from light, and subsequently used as feedstock
material for the FDM 3D printing.
Three-Point Bend Test
Cylindrical extruded filaments were tested regarding
their mechanical properties utilizing a three-point bend test
with a TA-XT2i texture analyzer (Texture Technologies,
Hamilton, MA, USA). Approximately 45-mm-long filament
pieces were cut from the extruded filament strand and placed
on the three-bend rig sample holder (TA-95N, Texture
technologies) with a set gap of 25 mm. The measurements
were initiated when the trigger force of 5.0 g was exceeded
and were conducted with a speed of 10 mm/s. The measure-
ment endpoint was set to 15 mm. Measurements were
repeated ten times for each formulation, and the Exponent
software (version 6.1.5.0, Stable Micro Systems, Godalming,
UK) was used for data analysis.
Vapor Sorption Analysis
To evaluate the moisture uptake of the prepared
filaments, dynamic vapor sorption analysis was performed
using SPS11 (ProUmid, Ulm, Germany). For analysis, sam-
ples were dried to 0% relative humidity (RH). Afterwards,
RH was automatically increased up to 90% in steps of 10%
RH, when equilibrium (0.0100%/30 min) was reached for the
set climate stage. The time between weighing cycles was
10 min, and the minimum and maximum time per climate
cycle were 60 min and 72 h, respectively.
3D Printing
A MakerBot Replicator 2 (MakerBot Industries, Brook-
lyn, NY, USA) with custom-built air-cooled print head was
used for 3D printing of filaments replicating the feedstock
filament and various sized tablets. Prior to the printing step,
the 3D models were designed in Rhinoceros (version 4.0).
The designed replicated filaments were 40 mm long and
1.75 mm in diameter, while tablets were designed to be either
6, 8, or 10 mm in diameter and 2.5 mm in height. The designs
were saved as stereolithography (.stl) files and exported into
the MakerBot Desktop software (version 3.7.0.108) where
printing parameters were determined. The printing tempera-
ture was varied depending on the formulation from 165 to
195°C (Table I), the set layer height was 0.05 mm, the number
of outlines printed on each layer was set to two, and printing
and traveling speed of the print head was 90 mm/s and
150 mm/s, respectively. Two different infill levels were
investigated, 15% and 90%, to achieve tablets with different
porosities, as the infill level is an indicator of how densely the
material is being deposited inside the printed outlines. The
infill level for the 3D-printed filament strand was set to 90%
to mimic the dense structure of the hot-melt extruded
filament. Filaments and tablets were printed on a build
platform of glass covered with blue tape (MakerBot Indus-
tries) to improve the adhering to the build platform.
Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was performed
to evaluate thermal properties of the samples (raw materials,
hot-melt extruded filaments as well as 3D-printed tablets)
using the DSC 1 (Mettler Toledo, Columbus, OH, USA).
Samples (3 to 6 mg) were analyzed in pierced aluminum pans
in a heat-cool-heat cycle from − 20 to 250°C with a heating
and cooling rate of 10°C/min and 20°C/min, respectively. The
obtained data was further analyzed in the STARe software
(Version 9.20, Mettler Toledo).
Drug Content
Drug content of the feedstock material used for 3D
printing was measured in distilled water in order to evaluate
the uniformity of the prepared hot-melt extruded filaments.
Table I. Process Temperatures and Formulation Compositions for the Hot-Melt Extruded Formulations as well as Subsequently Applied
Temperatures During the Printing Step
Formulation Drug Polymer(s) Plasticizer HME T (°C) Print T (°C)
1 30% 50% HPC EF + 20% HPMC E5 150 185
2 30% 70% PEO N80 140 185
3 30% 65% HPC EF + 5% PEO N80 140 190
4 30% 60% HPMC E5 + 10% PEO N80 140 –
5 30% 40% HPC EF + 30% PEO N80 140 195
6 30% 40% HPMC K100 + 20% PEO N80 10% TPGS 120 –
7 30% 40% HPMC K100 + 30% PEO N750 155 –
8 30% 45% HPC HF + 25% PEO N750 130 185*
9 30% 20% RS PO + 20% RL PO +30% PEO N750 140 –
10 30% 60% HPC EF + 10% PEO N80 130 185
11 30% 20% RS PO + 20% RL PO +27.5% PEO N750 2.5% TEC 100 165
12 30% 40% HPC HF + 30% L100 130 170
13 30% 40% HPC HF + 30% E PO 130 175
HME hot-melt extrusion, T temperature
*Formulation 8 showed day-to-day variability regarding the printability and should therefore be considered as non-printable
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Briefly, 150 ± 6 mg of hot-melt extruded filaments pieces,
taken from random sections of the extruded strand, were
placed in 100 mL of distilled water and shaken at 120 rpm
(Multi-shaker PSU 20, Biosan, Latvia) for a minimum of 24 h.
Samples were diluted and subsequently measured utilizing a
UV-Vis spectrophotometer (Lambda 35, PerkinElmer, Singa-
pore) at 263 nm. Ten replicates of each formulation were
analyzed.
Drug content data for the 3D-printed tablets was
obtained from the dissolution study. Concisely, once the
dissolution for each tablet had reached a plateau around
100% drug release, the mean value of five subsequent time
points was calculated and reported as the drug content (mean
± SD, n = 3). Since the drug release for formulation, 13 had
not reached 100% for all the tablets after 24 h; the tablets
were kept in the dissolution vessels for another 22 h in room
temperature, and the absorbance was then measured
manually.
In Vitro Drug Release
In vitro drug release studies were performed for the pure
drug as received, hot-melt extruded filaments, 3D-printed
filaments, as well as 3D-printed tablets to assess the drug
release profiles from the formulations. Samples were accu-
rately weighed and placed in the vessels containing 900 mL of
phosphate buffer (pH 7.4) at 37 ± 0.5°C with paddles rotating
at 100 rpm (Sotax AT 7smart, Basel, Switzerland). Spiral
capsule sinkers were used for the 3D-printed tablets while the
pure drug and prepared filaments were measured as such.
Samples of the release media were automatically withdrawn
with a pump (Sotax CY 6, Basel, Switzerland), filtered (glass
microfiber filter GF/B, GE Healthcare Life Sciences, UK),
and measured at predefined time points utilizing an online
UV-Vis spectrophotometer (Lambda 35, PerkinElmer, Singa-
pore) at 263 nm. Samples were measured in triplicate. The
percent of drug released at the specific time points was
calculated based on the theoretical drug content (30% w/w)
in the samples.
RESULTS AND DISCUSSION
Hot-Melt Extrusion and 3D Printing
The FDM 3D printing process uses filament strands as
feedstock material. Hot-melt extrusion, which is an
established manufacturing method in the pharmaceutical
industry, was used to homogeneously incorporate the drug
in a polymer matrix and simultaneously produce filament
strands that could be used in the printing process. In this
study, 13 formulations consisting of pharmaceutical grade
polymers were successfully hot-melt extruded with a drug
loading of 30% (w/w). One drug loading was used to support
the basic scenario that this kind of manufacturing technique
would be used in a hospital pharmacy setting where fixed-
dose filaments would be provided for 3D printing of flexible
dose tablets. An increased or decreased drug loading would
alter the drug release as previously reported (18,35). A 30%
(w/w) drug load was expected to be sufficient to achieve an
adequate amount of drug in the final dosage form, although
still resulting in drug release differences between the formu-
lations originating from the polymers used.
The desired filament diameter was 1.75 mm for optimal
performance in the MakerBot 3D printer as stated by the
manufacturer. Polymer properties, e.g., die swell observed for
viscoelastic materials, will have an effect on the diameter of
the extruded filament. As the screw speed and die size used in
this study were the same for all formulations, the speed of the
conveyor belt was adjusted to obtain filaments within the
desired diameter range. It was observed that if the filament
diameter was too small, the output of material from the
printer was decreased and too large of a filament diameter led
to no extrusion of material, which in both cases caused
fluctuation in material flow and typically failed printings. An
uneven filament diameter has previously been reported to
cause inconsistent deposition of the material and therefore,
poor printing outcome as the filament diameter will deter-
mine the feeding rate of the filament (36). The diameter of
the produced filaments is consequently of high importance to
achieve accurate and successful printing, which naturally is
required in the pharmaceutical industry.
Three different tablet sizes (⌀ 6, 8, and 10 mm), each
with two different infill levels (15% and 90%) were printed to
support the scenario that hospital pharmacies could 3D print
tablets of different doses and properties using pre-made
filaments. Additionally, cylindrical strands representing the
hot-melt extruded filaments were printed (Fig. 1) in order to
get an understanding of whether the 3D printing process, at
elevated temperatures, would affect the release properties
when the geometry and therefore the surface area was kept
unchanged. An increased temperature was required to
efficaciously 3D print the filaments compared to the temper-
ature required for hot-melt extrusion of filaments, which can
be explained by the lack of shear stress during printing as
compared to the hot-melt extrusion process (Table I).
Eight out of the 13 extruded formulations were success-
fully printed into the described geometries. The weight of the
different sized tablets varied depending on the formulation
and the printed infill from 59.2 ± 0.5 mg to 88.7 ± 2.7 mg,
107.6 ± 1.3 mg to 145.2 ± 1.0 mg, and 143.8 ± 1.2 mg to 236.7 ±
3.1 for the ⌀ 6, 8, and 10 mm tablets, respectively (Table II).
The weight differences between the printed tablets for the
different formulations most likely originate from the different
melt flow properties of the prepared filaments at the applied
temperatures. Melt flow behavior of a material, that is
temperature dependent, has been identified as an important
parameter in 3D printing affecting the printability and quality
of the printed object (36,37). It is worth noticing that all the
different formulations in this study, with an exception of the
printing temperature, were printed with the same settings
(settings optimized for PLA by the manufacturer) and that
rheological studies of the produced filaments preferably
should be carried out to successfully optimize the printing
parameters for the different formulations to further improve
the printing outcome. However, when three different sized
tablets were printed for each formulation, a linear increase in
the tablet weight was observed, indicating that aimed doses of
isoniazid can be fabricated utilizing FDM 3D printing.
Moreover, R2 values for the printed formulations were for
most formulations in a similar range as the reference material
PLA underlining that the prepared filaments were as suitable
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for FDM 3D printing as the optimized material with regard to
manufacturing of tablets with different doses. Tablets
containing isoniazid were printed in batches of three tablets
per batch. The standard deviation was generally low within
the batch, but a more substantial deviation could be seen for
some of the formulations between the printed batches (data
not shown). The greater deviation between the printed
batches may be explained by the fact that the produced
filaments were uneven in diameter or due to poor flow of the
material in the print head after long printing times.
Furthermore, as the printing took place in a non-controlled
environment, day-to-day changes in the ambient temperature
and humidity were likely to have an effect on how the
filament behaved in the printer. Filament optimization and a
printer with a controlled environment in the printing chamber
would, therefore, be beneficial to further advance the printing
outcome.
Printability
Formulations composed of HPC showed good printabil-
ity as six out of the eight printable filaments in this study
contained HPC. These formulations contained 40–65% (w/w)
HPC (EF or HF), and it is thus evident that both of these
HPC grades possesses good material properties for 3D
printing. HPC is a non-ionic water-soluble cellulose ether
with versatile properties (38). It has glass transition temper-
atures at 0°C (originating from a beta transition) and 120°C
which make it easily extrudable as the viscosity of the melt
significantly drops at the applied temperatures during print-
ing. Furthermore, the beta transition around 0°C results in
increased flexibility of the polymer, which is desired for
successful FDM 3D printing. Formulations containing HPMC
were not printable, except for formulation 1, containing only
20% (w/w) HPMC and a greater portion of HPC (50% (w/
w)). Hence, HPMC was found to be an unsuitable polymer
for printing applications in the range of 40–60% (w/w) in this
study. The addition of 10% (w/w) plasticizer to formulation 6
resulted in a filament that was too soft. Previous studies have
reported successful 3D printing of HPMC (28,39–41). How-
ever, the composition of the formulations reported was
different than the ones used in this study. Formulations
containing PEO in the range of 5–70% (w/w) were identified
as printable when PEO was used as a single polymer together
with the drug or in combination with HPC. Formulations
containing PEO and HPMC were not printable, which may
be attributed to a high concentration of HPMC in the
formulations (40–60% (w/w)) as compared to PEO (10–30%
(w/w)). Formulation 9 containing PEO (30% (w/w)),
Eudragit RS PO (20% (w/w)), and RL PO (20% (w/w))
was not successfully printed but could be printed when 2.5%
(w/w) of the plasticizer TEC was added to the formulation
prior to extrusion. Other Eudragit grades were also success-
fully printed when combined with HPC HF.
The printability of a material in a FDM 3D printer is
dependent on many factors. Fuenmayor et al. (36) suggested
that the material should be considered in relation to the
feeding, heating, and deposition processes during 3D printing
as all of these bring specific challenges. A printable filament
should have properties suitable for all of the abovementioned
process zones. Aho et al. (42) have proposed that rheological
studies in combination with thermal and mechanical studies
Fig. 1. a Three different sized tablets as well as a filament strand were designed and imported into the
printing software where the printing parameters were determined. b The designs were subsequently printed
with drug-loaded filaments and further analyzed
Table II. Weights of the 3D-Printed Tablets for the Different Formulations and Their Size and Weight Relationship, Mean ± SD, n = 6 (n = 3
for PLA)
6 mm, 15% (mg) 6 mm, 90% (mg) 8 mm, 15% (mg) 8 mm, 90% (mg) 10 mm, 15% (mg) 10 mm, 90% (mg) R2, 15% R2, 90%
PLA 76.4 ± 0.6 83.9 ± 0.5 135.8 ± 0.2 150.1 ± 1.1 210.3 ± 1.3 235.1 ± 2.7 0.9958 0.9948
1 88.7 ± 2.7 77.7 ± 3.4 141.2 ± 4.5 145.2 ± 1.0 181.5 ± 2.2 220.8 ± 4.5 0.9942 0.9989
2 61.6 ± 0.7 65.3 ± 0.6 107.6 ± 1.3 116.2 ± 5.3 143.8 ± 1.2 170.0 ± 0.8 0.9952 0.9997
3 59.2 ± 0.5 69.4 ± 5.3 133.2 ± 0.4 141.4 ± 2.0 195.0 ± 7.2 192.0 ± 8.1 0.9973 0.9900
5 59.2 ± 1.7 67.8 ± 2.2 140.0 ± 3.4 144.5 ± 4.1 203.6 ± 12.6 236.7 ± 3.1 0.9996 0.9972
10 70.8 ± 1.0 73.5 ± 0.9 121.5 ± 2.4 130.1 ± 2.1 193.4 ± 5.2 205.9 ± 1.7 0.9902 0.9930
11 66.1 ± 1.2 73.7 ± 2.1 141.4 ± 4.9 136.5 ± 0.6 208.3 ± 10.0 222.5 ± 1.9 0.9988 0.9920
12 68.1 ± 2.6 74.7 ± 0.7 115.9 ± 1.8 133.4 ± 4.8 196.5 ± 8.1 214.8 ± 4.7 0.9786 0.9913
13 64.5 ± 0.7 73.6 ± 2.6 130.0 ± 3.7 143.4 ± 5.4 163.1 ± 2.1 165.7 ± 0.9 0.9651 0.9182
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can be used to predict the extrudability and 3D printability of
formulations. In this study, to gain initial understanding about
the printability of produced filaments, their mechanical
properties as well as tendency to absorb or adsorb moisture
were studied.
Mechanical Testing of the Prepared Filaments
To successfully be able to load and subsequently 3D print
the prepared formulations, the filament needs be flexible but
not too soft (43). A brittle filament will break under the
pressure from the driving gears and prevent feeding, while a
too soft filament may inhibit feeding when the material is
squeezed between the driving gears (28,36). In this study, a
three-point bend test setup was used as a fast method to get
an initial understanding of the mechanical properties of the
prepared filaments. Commercially available PLA filaments
that possess optimal mechanical properties for the used
printer were chosen as a reference material. When comparing
the printability of the different formulations with the breaking
distance values gained from the three-point bend test, it was
observed that filaments with a higher breaking distance
(toughness) had a tendency to be printable while filaments
with a breaking distance below 1.5 mm were too brittle to be
loaded into the print head of the 3D printer (Table III). This
is in accordance with what has been reported by Zhang et al.
(28) for another type of FDM 3D printer where it was found
that the produced filaments should be sufficiently stiff
possessing a breaking stress greater than 2941 g/mm2 and a
breaking distance over 1 mm for successful loading and
printing. Another study reported that filaments should have a
breaking distance over 1.125 mm to ensure printability (44).
The obtained values for breaking stress, representing the
stiffness of the filaments were on the other hand not in
accordance with the findings reported by Zhang et al. (28).
The breaking stress for the printable filaments in this study
was in the range of 3126–7638 g/mm2, while the filaments that
were not successfully printed had breaking stress values
between 1335 and 5119 g/mm2. As these results show no
clear trend, it can be concluded that the printability of the
filaments is a complex matter where more than one
mechanical parameter needs to be taken into account to be
fully understood. It was detected that even though a filament
may have a sufficient breaking distance, it may be too soft for
successful printing leading to deformation of the filament
under the pressure of the driving gears. This will result in
unsuccessful feeding of the filament, as it can no longer be
gripped by the driving gears. Some filaments were also
observed to be subjected to wear deriving from the driving
gears, seen as small filament pieces being worn off the surface
of the filament, which also eventually resulted in failed
feeding of the filament towards the nozzle. Based on this
study, the fast three-point bend test can be used as an initial
indicator regarding printability; however, as the breaking
distance is a measure of brittleness, additional mechanical
tests concerning the material properties such as the column
strength, Young’s modulus, and softness of the filaments
should also ideally be performed (36,44).
Vapor Sorption
Water uptake for solid dosage forms is of interest as it
may negatively affect the physicochemical, chemical, and
microbiological stability of the product (45). As new
manufacturing methods are introduced to the pharmaceutical
field, new process challenges are also encountered. For FDM
3D printing, poor quality, failed prints, and reduced printing
times have been reported due to possible moisture uptake of
the feedstock material as some polymers are known to readily
absorb moisture from the air (46). The amount of moisture
absorbed is dependent on multiple factors such as relative
humidity, temperature, affinity between the surface of the
material, and the water molecules as well as the surface area
of the sample (47). Absorbed moisture has been reported to
cause a slight increase in the filament diameter as well as
fluctuations in the glass transition temperature for the
filament leading to inconsistent printing performance (48).
Consequently, day-to-day variations regarding printability
Table III. The Brittleness and Stiffness of the Prepared Hot-Melt Extruded Filaments Were Determined by a Three-Point Bend Test Where
the Distance (mm) Until the Filament Broke and Breaking Stress (g/mm2) Was Recorded and Used as an Indicator if the Filament Would Be
3D Printable (Mean ± SD, n = 10)
Formulation Breaking distance (mm) Breaking stress (g/mm2) Printable
PLA 3.69 ± 0.28 15,361.45 ± 2064.55 Yes
1 2.39 ± 0.43 5456.12 ± 769.68 Yes
2 1.93 ± 0.13 3125.75 ± 185.30 Yes
3 3.50 ± 1.09 5046.78 ± 1324.55 Yes
4 0.83 ± 0.05 3145.73 ± 265.98 No
5 2.80 ± 0.62 4982.93 ± 604.85 Yes
6 0.90 ± 0.19 1334.48 ± 67.08 No
7 2.70 ± 0.47 5119.04 ± 369.75 No
8 4.07 ± 0.94 4662.66 ± 625.93 No*
9 1.24 ± 0.13 4251.27 ± 929.07 No
10 2.59 ± 0.32 3255.59 ± 294.42 Yes
11 2.31 ± 0.31 4988.52 ± 142.70 Yes
12 1.78 ± 0.26 7637.32 ± 808.91 Yes
13 2.93 ± 0.28 6496.31 ± 443.79 Yes
*Day-to-day variability regarding printability, as the filament deformed during feeding, which occasionally failed the prints
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and quality are to be expected for some materials if the
printing process does not take place in a controlled environ-
ment. In this study, the hot-melt extruded filaments were
analyzed with regard to their moisture uptake to investigate if
it could be linked to the printability of the filaments. All
prepared filaments absorbed moisture in a sigmoidal manner
with low moisture uptake at low humidity and high uptake at
higher RH (Fig. 2), which is typical for cellulose- and starch-
based polymers (45). At low RH, the increase in mass (%) for
the different formulations was small, e.g., between 0.33% and
0.71% at 30% RH and even at 60% RH, the change of mass
was less than 4% for all of the formulations (data for all RH
studied available in supplemental 1). At 90% RH, however,
the moisture uptake was rapidly intensified for all the
filaments. Formulation 4 displayed the greatest weight
increase at 90% RH with a total increase of 45.78%. No
clear trend could be seen regarding printability and moisture
uptake at low RHs. However, based on the data obtained
from this study, it appears that filaments that have a high total
uptake of moisture have a tendency to be unprintable. A
common factor for all the formulations with a high moisture
uptake at high RH was that they all contained either PEO
N750 or HPMC E5 or K100, indicating that the major
moisture uptake can be attributed to these polymers.
DSC
The thermal properties of the raw materials, hot-melt
extruded filaments, as well as 3D-printed tablets were
investigated in order to gain information about how the
formulation changed during the different processing steps.
Unprocessed isoniazid melted during the first heating run
with a sharp endothermic peak onset at 170.5°C and a max
peak located at 170.7°C (Fig. 3). The DSC thermograms from
the first heat scan were similar for the hot-melt extruded
filaments as when they were further processed into 3D-
printed tablets. This indicates that no major changes take
place when the material is reheated to elevated temperatures
during 3D printing of the material, it would appear that no
degradation of the drug occurs during 3D printing. From the
thermograms of the physical mixtures, hot-melt extruded
filaments as well as the 3D-printed tablets, it is evident that
the drug starts dissolving in the polymer around 100°C before
finally reaching a larger endothermic peak identified as the
melting point of isoniazid. Generally, a small melt point
depression of the drug as well as broadening of the
endothermic peak for the hot-melt extruded filament as
compared to the physical mixture was observed. Further melt
point depression was discovered for some of the 3D-printed
tablets compared to the hot-melt extruded filament, when
being further processed at temperatures close to or above the
melting point of the drug. This can be attributed to an
increased amount of the drug being dissolved or dispersed in
the polymer matrix resulting in a reduction of the chemical
potential of the system due to interaction between the
materials. Other endothermic events present during the first
heating were typically broad and located between 15 and
100°C, which originate from dehydration of the polymers due
to the hygroscopic nature of the polymers present in the
formulation (29). Other, more sharp, melting peaks could be
attributed to melting of the polymer as they were in
agreement with the melting peak present for the pure
polymer. No completely amorphous formulations were ob-
tained, neither by hot-melt extrusion nor by further 3D
printing the material as all formulations showed endothermic
peaks during the first heating. However, as isoniazid is a
highly water-soluble drug, the main goal of utilizing hot-melt
extrusion in this study was to prepare drug-loaded filaments
suitable for 3D printing rather than create amorphous
formulations.
Fig. 2. Mass change (%) with offset correction over time (h) at different RHs for the hot-melt
extruded filaments. Formulations 2 and 12 are missing from the graph, due to technical problems
during the measurement. However, data regarding mass change vs RH for these formulations can
be found in the supplementary material. Unprintable formulations are marked with a square at the
end of the line. RH relative humidity
Page 7 of 13 52AAPS PharmSciTech (2019) 20: 52
During the second heating of the material, the melting
peaks were in general smaller than during the first run and
also amorphous material was formed as no melting or
crystallization peaks were present on the thermograms
(supplemental 2). The single phase formed during the second
heating when the thermal history of the material was
removed could either be seen for all types of formulations
(physical mixture, hot-melt extruded filament, or the 3D-
printed tablet) or only for the hot-melt extruded filament and/
or 3D-printed tablets that were processed at high
temperatures.
The only formulation where a distinctive change (except
for melt point depression) between the hot-melt extruded
filament and the 3D-printed tablet was observed during the
first heating was formulation 1 containing isoniazid, HPC EF,
and HPMC E5. The thermogram for the 3D-printed tablet
showed that the drug started melting in the polymer at
around 70°C. The melting peak onset and the max peak are
located at 139.4°C and 159.1°C, respectively. The hot-melt
extruded filament of formulation 1, on the other hand,
displayed a split melting peak with max peaks located at
159.1°C and 171.3°C, respectively. The difference between
the thermograms for the hot-melt extruded filament and the
3D-printed tablet may be explained by the higher tempera-
ture applied during 3D printing compared to the hot-melt
extrusion process. However, since the physical mixture of
formulation 1 did not possess a split peak, but one single
melting peak, it is more likely that a phase separation
between the polymer and the drug had occurred during long
storage times of the filament and that a single phase was
reformed during the printing process when high temperatures
were applied.
Drug Content of Hot-Melt Extruded Filaments and 3D-
Printed Tablets
All produced hot-melt extruded filaments and 3D-
printed tablets had a target drug load of 30% (w/w) isoniazid
in order to obtain a sufficient amount of drug in the final
tablets. The produced filaments that were printable and the
3D-printed tablets were confirmed to have a drug load
between 27.9 ± 2.6% and 31.7 ± 0.2% and 27.5 ± 1.1% and
34.7 ± 0.2%, respectively (Table IV). Hot-melt extruded
filament strands and subsequently 3D-printed tablets
displayed a drug load in the same range, suggesting that no
drug degraded during the printing process. Overall, the 3D-
Fig. 3. Thermograms (endo up) from the first heating run for the different printable
formulations (a–h). Raw materials are presented in grey and formulation mixtures in blue.
PM physical mixture, HME hot-melt extruded filament, 3DP 3D-printed tablet
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printed tablets had a smaller standard deviation than the
starting material, which may be explained by the fact that for
printing, a smaller length of the filament was used as
compared to the filament content analysis where the filament
pieces at random locations were cut off from the filament
strand. However, the generally small standard deviation
indicated that the hot-melt extrusion process produced
homogenous filaments.
In Vitro Drug Release
In vitro drug release revealed that hot-melt extruded
filaments with different release profiles were successfully
prepared, which was even more pronounced when the filaments
were further processed into 3D-printed dosage forms (Fig. 4).
This showed that both the formulation development and the 3D
printing parameters are important factors that will have an effect
on how the drug is released. The various 3D-printed tablets
presented in Fig. 4b (8 mm, 90% infill) showed an 80% drug
release that ranged from 40 to 852 min, which confirms that
personalized dosage forms with tailored isoniazid release for
prevention of latent tuberculosis may be achieved utilizing 3D
printing. All formulations started releasing the drug immedi-
ately when placed in the dissolution media, as the drug was
present also on the surface of the tablet since no coating was
applied. Formulation 2, containing PEO, showed the fastest
drug release of all formulations. It was expected that this
formulation would release the drug rapidly as PEO is a
hydrophilic polymer that hydrates quickly to form a gel layer
on the surface of the tablet that facilitates the release of the drug.
Since PEO is non-ionic polymer, no interaction between drug
and polymers is to be expected (49). The most sustained drug
release of the prepared 3D-printed tablets was observed for
formulation 13, which did not reach a complete 100% drug
release during the 24 h sampling period. This formulation could
be suitable for a once daily administration approach, which may
be beneficial for adherence. The formulation was projected to
show a sustained drug release as HPC HF is a hydrophilic, high
molecular weight (MW= 1,150,000) polymer that typically is
used in the range of 15–35% (w/w) for manufacturing of
controlled release conventional tablets (38). Eudragit E PO
was combined with HPCHF due to its swellable and permeable
properties at a pH above 5.0. Furthermore, the polymer acts as
taste- and odor-masking agents and protects the drug against
light and moisture, which may be advantageous for the light-
sensitive drug. In addition, the taste-masking properties can be
beneficial with regard to adherence to the treatment. Formula-
tion 12, containing Eudragit (L100) and HPC, released 80% of
the drug within 334 min (8 mm, 90%) and was thus the second
slowest formulation prepared in this study. Formulation 10 and
11 showed similar release of the drug from the 3D-printed 8mm,
90% tablets and were the formulations that showed the fastest
drug release after formulation 2.
The impact of the tablet size on the drug release was not
very prominent. However, as expected, a trend where ⌀
6 mm tablets released the drug the fastest and the 10 mm
tablet the slowest, which can be attributed to the surface area
of the tablets, was observed. It has previously been reported
that the geometrical shape of the FDM 3D-printed tablet
affects the drug release profile (32,50). The surface area to
volume ratio is thus important to take into account when
aiming for a certain drug release profile, as an increased
surface area to volume ratio have been reported to have a
faster drug release. The tablet size and drug release
dependency trend was more noticeable for the sustained
release formulation than for the formulations that release the
drug rapidly as shown in the examples in Fig. 5. The drug
release from the hot-melt extruded filaments was in all cases
faster than the further processed 3D-printed tablets (Figs. 4
and 5b), which again may be explained by the difference in
surface area. When a filament strand was 3D-printed to
mimic the filament used as feedstock material, a similar
release profile was observed, suggesting that the additional
processing of the material at elevated temperatures during
the 3D printing step did not alter the drug release properties
nor cause degradation of the drug. This is in accordance with
the results from the DSC and the drug content analysis. The
stability of the drug during 3D printing, despite in some cases
exposure to temperatures above the melting point of the
drug, may be explained by the short contact time with the
heating block during the printing step compared to the hot-
melt extrusion process where the material is heated up for a
much longer time (30). Moreover, the stability of the drug at
higher temperatures may be linked to the lower shear forces
Table IV. Drug Content (%) for 3D-Printed Tablets (Different Sizes and Infill Levels) as well as Hot-Melt Extruded Filaments That Served as
Starting Material in the Printing Process
% API in 3D-printed tablets and hot-melt extruded filament (w/w)
6 mm, 15% 6 mm, 90% 8 mm, 15% 8 mm, 90% 10 mm, 15% 10 mm, 90% Filament
1 31.6 ± 0.2 28.0 ± 1.7 30.4 ± 0.2 31.2 ± 1.4 27.5 ± 1.1 29.9 ± 1.3 27.9 ± 2.6
2 30.6 ± 0.3 30.8 ± 0.1 30.1 ± 0.7 30.9 ± 0.0 30.4 ± 0.1 30.6 ± 0.1 30.2 ± 1.0
3 31.0 ± 0.1 30.9 ± 0.1 31.1 ± 0.1 31.0 ± 0.0 30.9 ± 0.1 30.7 ± 0.1 31.7 ± 0.2
5 30.3 ± 0.5 30.5 ± 0.1 30.6 ± 0.2 30.8 ± 0.0 31.3 ± 0.0 30.7 ± 0.1 29.6 ± 1.2
10 34.7 ± 0.2 34.6 ± 0.1 32.8 ± 0.4 33.4 ± 0.4 34.3 ± 0.1 30.4 ± 0.4 31.3 ± 1.8
11 31.8 ± 0.1 32.1 ± 0.1 31.6 ± 0.0 30.9 ± 0.0 31.2 ± 0.1 31.0 ± 0.1 31.0 ± 0.3
12 30.2 ± 0.4 30.9 ± 0.1 31.1 ± 0.1 30.3 ± 0.0 30.4 ± 0.1 30.7 ± 0.1 29.7 ± 1.1
13 31.1 ± 0.1 30.8 ± 0.3 30.8 ± 0.1 30.8 ± 0.2 30.9 ± 0.0 30.3 ± 0.1 30.2 ± 0.6
The theoretical drug content for all formulations was 30% (w/w). Data presented as mean ± SD, n = 3 for the 3D-printed tablets and n = 10 for
the HME filaments
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present during 3D printing compared to the hot-melt
extrusion step.
Printed infill levels have previously been reported to
alter the drug release (39,51). In this study, tablets with
different inner porosities were printed to understand to which
extent the drug release of the printed tablets could be fine-
tuned by this feature. Different inner porosities were attained
by printing tablets with different infill levels, namely 15% and
90%, resulting in an almost completely void and solid infill,
respectively. The drug release studies revealed that the effect
of the infill for most formulations was fairly small
(supplemental 3), which can be explained by the fact that
the default infill setting in the MakerBot Desktop software is
to print the set infill level for only 15% of the printed object.
It was noticed that during the first 45% of the printed object,
the infill level was in fact 100%, and only from 45 to 60%
printing occurred with the set infill level (15% or 90%). The
rest of the object was then again printed with 100% infill. By
increasing the percentage of the tablet that is printed with the
set infill level, differences in the release profile of the drug
from the printed tablets ought to be greater. It has been
reported previously that the difference in drug release was
not statistically significant when the tablet was printed with a
base and a cap; nevertheless, a much faster drug release was
observed when no base or cap, only infill, was printed (39).
By printing such tablets, the inner parts of the tablet can
immediately come in contact with the dissolution media and
be wetted where tablets printed with a solid outer shell will
release the drug slower as the surface area in contact with the
release media is smaller.
Fig. 4. a Drug release of isoniazid from hot-melt extruded filaments and b drug release from 3D-
printed tablets with a size of ⌀ 8 mm and a 90% infill level compared to pure drug. Data presented
as mean ± SD, n = 3
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The in vitro drug release of the printed dosage forms
possessed versatile properties, highlighting the possibility to
tailor the dosage form according to the patient’s need and
requirements. Depending on the preferences as well as the
metabolic rate of isoniazid in the treated patient, one of the
presented formulations could be used for prevention of latent
tuberculosis as both the dose and drug release can be
adjusted. This study presents formulations suitable for a once
a day (formulations 12 and 13) as well as multiple times a day
(formulations 1, 2, 3, 5, 10, and 11) administering approach.
This study furthermore demonstrated that 3D printing
enables production of different doses and drug release
profiles by simply changing the digital design. The flexibility
of 3D printing makes the technique attractive for production
of personalized dosage forms compared to conventional
manufacturing methods where for example punches and dies
need to be changed when a different tablet size is needed.
CONCLUSIONS
In this study, drug-loaded feedstock material for FDM 3D
printing was prepared utilizing hot-melt extrusion. Studying the
prepared filaments revealed that breaking distance was a good
initial predictor regarding printability and that the moisture
uptake of the filaments revealed a trend, where unprintable
filaments typically showed a greater total moisture uptake as
compared to the printable formulations. Thirteen different
formulations with suitable properties for oral drug delivery
were produced and eight out of these were subsequently
successfully processed into tablets of different sizes and infill
levels using a Makerbot 3D printer. All printable formulations
showed good correlation between the printed tablet size and
mass of the tablet, highlighting the potential to utilize 3D
printing for production of personalized doses for prevention of
latent tuberculosis. The possibility to easily adjust the dose
according to the weight and metabolic rate of the patient is
expected to improve the efficacy and adherence to the therapy.
In addition, in vitro drug release of the printed dosage forms
revealed versatile properties, making it possible to administer
the dosage form once or multiple times a day depending on the
need and requirements of the patient. Due to the sustained
isoniazid release, formulations 12 and 13 could be taken once
daily, where formulations 1, 2, 3, 5, 10, and 11, that released the
drug faster, would be suitable for a multiple times a day
administering approach. This study further highlights that by
combining formulation development of the feedstock material
with the endless geometrical potentials associated with 3D
printing, personalized oral dosage forms with nearly limitless
properties can be produced.
It has been shown in the present study and previously by
other scientists that different release patterns may be
obtained by varying the printed structure and infill level.
One next step would be to develop a software that could
calculate the required mass to be printed as well as the
release profile by entering parameters such as feedstock
material, dosage form size, infill level, and structure if this
treatment decision and manufacturing would be done at the
point-of-care. By doing so, 3D printing could become an even
more attractive manufacturing method within the pharma-
ceutical field and could likely take a step towards being an
established manufacturing method in, e.g., hospital pharma-
cies so that patients sooner could benefit from dosage forms
tailored according to their needs.
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